ZNF77 and neoplasm: Considering miR‐126 replacement as a possible therapeutic option, we evaluated the expression level of miR‐126‐3p in these patients’ derived metastatic cell lines (Pt1, Pt2, Pt3, Pt4) by comparing its amount with that expressed by the primary tumor counterpart of Pt4 and the A375M cell line.